Question 1

How many sequences was Aptamer Group PLC's internal AI discovery model trained on?

Accepted Answer

Aptamer Group PLC's internal AI discovery model was trained on approximately 450,000 sequences covering 42 protein targets.

Question 2

What radiochemical purity has Aptamer Group PLC achieved for its radiolabelling for radioligand therapy work?

Accepted Answer

Aptamer Group PLC achieved radiolabelling for its radioligand therapy work at greater than 99% radiochemical purity and at activities comparable with clinical applications.

Question 3

What is Aptamer Group plc's folic acid rapid test project status?

Accepted Answer

Aptamer Group plc is in in‑house validation of a Gates Foundation/Imperial College London folic acid rapid test (completion expected July 2026), with transfer to Imperial for device integration and field validation anticipated by the end of 2026.

Question 4

What does Aptamer Group's asset base centre on?

Accepted Answer

Aptamer Group's asset base centres on its Optimer® synthetic binders and related intellectual property, together with fee-for-service operations that supply Optimer materials and binder development to academic and commercial partners.

Question 5

What did APTAMER GROUP PLC report for its sales pipeline at the January half-year update?

Accepted Answer

APTAMER GROUP PLC reported a sales pipeline of £4.8m at the January half-year update, an increase of 55% from £3.1m at the prior update.

Question 6

How is Aptamer Group changing its revenue model?

Accepted Answer

Aptamer Group is transitioning from predominantly fee‑for‑service income toward higher‑margin licensing and royalty revenues.

Timeline

APTAMER

Aptamer Group posts 25% revenue growth and first licensing income

Aptamer Group launches Gates Foundation‑backed programme to build rapid folate test

More in Biotech

IP Group leads £4m funding round for AI materials spin-out

Genflow wins Japanese patent allowance for SIRT6 therapy

Scancell widens annual loss

Sareum signals intention to launch equity capital raise

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

Poolbeg Pharma secures South Korean patent for POLB 001

Avacta raises £12.5m in placing and subscription

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

Fusion Antibodies relaunches website to sharpen customer focus

Cardiogeni shares suspended on delayed annual accounts

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer